News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
277,449 Results
Type
Article (14424)
Company Profile (101)
Press Release (262918)
Multimedia
Podcasts (69)
Webinars (14)
Section
Business (88353)
Career Advice (467)
Deals (15429)
Drug Delivery (82)
Drug Development (36760)
Employer Resources (50)
FDA (6410)
Job Trends (6241)
News (150866)
Policy (14137)
Tag
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (449)
Accelerated approval (22)
Adcomms (9)
Allergies (93)
Alliances (23320)
ALS (68)
Alzheimer's disease (515)
Antibody-drug conjugate (ADC) (150)
Approvals (6699)
Artificial intelligence (257)
Autoimmune disease (76)
Automation (20)
Bankruptcy (151)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (148)
Biotechnology (39)
Bladder cancer (51)
Brain cancer (39)
Breast cancer (204)
Cancer (1651)
Cardiovascular disease (196)
Career advice (421)
Career pathing (14)
CAR-T (61)
CDC (7)
Cell therapy (191)
Cervical cancer (18)
Clinical research (32471)
Collaboration (918)
Company closure (1)
Compensation (382)
Complete response letters (44)
COVID-19 (785)
CRISPR (53)
C-suite (613)
Cystic fibrosis (60)
Data (2421)
Decentralized trials (1)
Denatured (18)
Depression (59)
Dermatology (14)
Diabetes (152)
Diagnostics (1443)
Digital health (13)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (151)
Drug pricing (121)
Drug shortages (15)
Duchenne muscular dystrophy (96)
Earnings (34211)
Editorial (24)
Employer branding (4)
Employer resources (46)
Events (39745)
Executive appointments (598)
FDA (7770)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (528)
Gene editing (84)
Generative AI (24)
Gene therapy (199)
GLP-1 (482)
Government (1427)
Grass and pollen (4)
Guidances (172)
Healthcare (3625)
HIV (16)
Huntington's disease (10)
IgA nephropathy (48)
Immunology and inflammation (82)
Immuno-oncology (28)
Indications (92)
Infectious disease (879)
Inflammatory bowel disease (85)
Inflation Reduction Act (7)
Influenza (28)
Intellectual property (132)
Interviews (60)
IPO (5921)
IRA (33)
Job creations (2058)
Job search strategy (374)
JPM (29)
Kidney cancer (11)
Labor market (32)
Layoffs (208)
Leadership (10)
Legal (3450)
Liver cancer (25)
Longevity (9)
Lung cancer (222)
Lymphoma (147)
Machine learning (14)
Management (17)
Manufacturing (539)
MASH (89)
Medical device (1312)
Medtech (1326)
Mergers & acquisitions (10006)
Metabolic disorders (540)
mRNA (61)
Multiple sclerosis (59)
NASH (15)
Neurodegenerative disease (104)
Neuropsychiatric disorders (46)
Neuroscience (1029)
Neurotech (1)
NextGen: Class of 2026 (1589)
Non-profit (605)
Now hiring (22)
Obesity (279)
Opinion (151)
Ovarian cancer (64)
Pain (135)
Pancreatic cancer (68)
Parkinson's disease (105)
Partnered (11)
Patents (268)
Patient recruitment (164)
Peanut (15)
People (30156)
Pharmaceutical (60)
Pharmacy benefit managers (19)
Phase 1 (8418)
Phase 2 (13714)
Phase 3 (12387)
Pipeline (3305)
Policy (147)
Postmarket research (1402)
Preclinical (3398)
Press Release (25)
Prostate cancer (109)
Psychedelics (20)
Radiopharmaceuticals (155)
Rare diseases (447)
Real estate (2668)
Recruiting (19)
Regulatory (11324)
Reports (16)
Research institute (581)
Resumes & cover letters (56)
Rett syndrome (9)
RNA editing (8)
RSV (24)
Schizophrenia (86)
Series A (107)
Series B (60)
Service/supplier (2)
Sickle cell disease (54)
Special edition (11)
Spinal muscular atrophy (84)
Sponsored (11)
Startups (1651)
State (2)
Stomach cancer (6)
Supply chain (61)
Tariffs (71)
The Weekly (49)
Vaccines (266)
Venture capital (38)
Weight loss (164)
Women's health (47)
Worklife (4)
Date
Today (26)
Last 7 days (186)
Last 30 days (1113)
Last 365 days (10336)
2026 (4606)
2025 (10711)
2024 (12494)
2023 (14248)
2022 (19557)
2021 (20067)
2020 (19031)
2019 (14884)
2018 (11713)
2017 (13887)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (322)
Alabama (20)
Alaska (1)
Arizona (85)
Arkansas (4)
Asia (21176)
Australia (2731)
California (3837)
Canada (1755)
China (701)
Colorado (170)
Connecticut (153)
Delaware (159)
Europe (41547)
Florida (727)
Georgia (75)
Hawaii (1)
Idaho (11)
Illinois (439)
India (63)
Indiana (296)
Iowa (2)
Japan (328)
Kansas (82)
Kentucky (21)
Louisiana (6)
Maine (2)
Maryland (488)
Massachusetts (3094)
Michigan (54)
Minnesota (200)
Mississippi (1)
Missouri (37)
Montana (9)
Nebraska (8)
Nevada (19)
New Hampshire (9)
New Jersey (1695)
New Mexico (7)
New York (1100)
North Carolina (730)
North Dakota (2)
Northern California (1802)
Ohio (92)
Oklahoma (5)
Oregon (18)
Pennsylvania (840)
Puerto Rico (17)
Rhode Island (18)
South America (508)
South Carolina (11)
Southern California (1694)
Tennessee (64)
Texas (550)
United States (15208)
Utah (65)
Virginia (201)
Washington D.C. (42)
Washington State (281)
West Virginia (1)
Wisconsin (49)
Wyoming (1)
277,449 Results for "saptalis pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Saptalis Pharmaceuticals Launches Fluoxetine Oral Solution, USP 20 mg/5 mL
June 18, 2025
·
1 min read
Press Releases
Saptalis Pharmaceuticals Announces the Launch of LIKMEZ® — The First and Only US FDA-Approved Ready-to-Use Oral Suspension of Metronidazole
May 21, 2025
·
2 min read
Business
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
Appili Therapeutics Inc. announced today it has amended its agreement with Saptalis Pharmaceuticals LLC o expand the territories in which Saptalis will commercialize ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole.
February 8, 2022
·
5 min read
Press Releases
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
May 27, 2026
·
1 min read
Press Releases
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
May 5, 2026
·
6 min read
FDA
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
Appili Therapeutics Inc. today announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC (“Saptalis”) received approval from the U.S. Food and Drug Administration (“FDA”) for Metronidazole Oral Suspension 500mg/5mL (ATI-1501).
September 25, 2023
·
5 min read
Press Releases
InMed Pharmaceuticals Amends Preferred Investment Options
May 19, 2026
·
1 min read
Press Releases
Newron Pharmaceuticals to Participate in June 2026 Investor Conferences
May 28, 2026
·
2 min read
Press Releases
Supernus Pharmaceuticals to Participate in June 2026 Investor Conferences
May 27, 2026
·
4 min read
Press Releases
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
May 27, 2026
·
3 min read
1 of 27,745
Next
